Intra-Cellular Therapies stock (US46116X1019): Q1 2026 earnings beat estimates with EPS growth

Intra-Cellular Therapies reported Q1 2026 results with adjusted EPS of $0.91, surpassing consensus estimates, driven by CAPLYTA sales growth amid strong demand in US bipolar disorder market.

Intra-Cellular Therapies released its first quarter 2026 financial results, posting adjusted earnings per share of $0.91, beating analyst expectations of $0.74. Revenue reached $169.5 million, up 30% year-over-year, primarily from CAPLYTA net sales of $168.2 million, according to the company press release as of May 1, 2026. The stock rose 4.2% in after-hours trading following the announcement.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Intra-Cellular Therapies, Inc.
• Sector/industry: Biotechnology / CNS therapeutics
• Headquarters/country: United States
• Core markets: US psychiatry
• Key revenue drivers: CAPLYTA (lumateperone)
• Home exchange/listing venue: Nasdaq (ITCI)
• Trading currency: USD

Intra-Cellular Therapies: core business model

Intra-Cellular Therapies develops novel drugs for central nervous system disorders, with CAPLYTA as its lead product approved for schizophrenia and bipolar depression in adults. The company focuses on therapies with improved safety profiles over existing antipsychotics, targeting the large US psychiatry market valued at over $20 billion annually, per IQVIA as of Q1 2026. CAPLYTA generated $168.2 million in Q1 2026 sales, reflecting robust adoption.

The business model emphasizes commercial execution in the US, where over 90% of revenue originates, making it highly relevant for US investors tracking biotech growth stocks on Nasdaq. R&D efforts center on label expansions and new indications to extend CAPLYTA's lifecycle.

Main revenue and product drivers for Intra-Cellular Therapies

CAPLYTA remains the sole revenue driver, with Q1 2026 prescriptions up 42% year-over-year to 1.02 million, per the earnings release. Net product sales grew 31% to $168.2 million, supported by expanded insurance coverage reaching 87% of US commercial lives. This positions Intra-Cellular Therapies strongly in bipolar I and schizophrenia treatments amid rising mental health awareness in the US.

Operating expenses rose modestly to $122.4 million in Q1 2026 from $105.3 million prior year, driven by sales and marketing investments, while R&D spend held at $32.1 million for ongoing trials including bipolar depression in adolescents, according to the 10-Q filing as of May 1, 2026.

Industry trends and competitive position

The US antipsychotic market grows at 5-7% CAGR through 2030, fueled by increasing diagnoses, per EvaluatePharma as of March 2026. Intra-Cellular Therapies differentiates CAPLYTA via its mechanism as a 5-HT2A and D2 receptor modulator with lower metabolic risks compared to rivals like Eli Lilly's olanzapine or Johnson & Johnson's Invega.

Market share for CAPLYTA reached 8.2% in Q1 2026, up from 5.9% a year earlier, capturing share from generics amid patent cliffs for older drugs.

Why Intra-Cellular Therapies matters for US investors

Listed on Nasdaq under ITCI, Intra-Cellular Therapies offers direct exposure to the expanding US mental health sector, where demand for innovative antipsychotics outpaces supply. With $550 million in cash reserves as of Q1 2026 end, the company funds growth without dilution risks, appealing to biotech investors focused on commercial-stage firms.

Main revenue and product drivers for Intra-Cellular Therapies

Guidance for 2026 full-year CAPLYTA sales reaffirmed at $775-825 million, implying 35-40% growth. Key catalysts include potential adolescent bipolar approval in 2H 2026 and adjunctive MDD data readout in 2027.

Conclusion

Intra-Cellular Therapies delivered solid Q1 2026 results with revenue and EPS beats, underscoring CAPLYTA's momentum in the US market. While execution on pipeline expansions remains key, the company's commercial focus and cash position provide a stable foundation. Investors monitor upcoming trial data and label updates for sustained growth potential.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.